255 related articles for article (PubMed ID: 32092974)
1. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.
Grimm MO; Leucht K; Grünwald V; Foller S
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32092974
[TBL] [Abstract][Full Text] [Related]
2. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
3. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
Chau V; Bilusic M
Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
[TBL] [Abstract][Full Text] [Related]
6. Developments in personalized therapy for metastatic renal cell carcinoma.
Fujiwara R; Kageyama S; Yuasa T
Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
[TBL] [Abstract][Full Text] [Related]
7. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.
Su Y; Fu J; Du J; Wu B
Ther Adv Med Oncol; 2020; 12():1758835920950199. PubMed ID: 32874210
[TBL] [Abstract][Full Text] [Related]
8. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
9. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.
Iacovelli R; Ciccarese C; Buti S; Zucali PA; Fantinel E; Bimbatti D; Verzoni E; Accettura C; Bonomi L; Buttigliero C; Fornarini G; Pipitone S; Atzori F; Masini C; Massari F; Primi F; Strusi A; Giudice GC; Perrino M; Maruzzo M; Milella M; Giannarelli D; Brunelli M; Procopio G; Tortora G
Eur Urol; 2024 Mar; ():. PubMed ID: 38521617
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
Mori K; Mostafaei H; Miura N; Karakiewicz PI; Luzzago S; Schmidinger M; Bruchbacher A; Pradere B; Egawa S; Shariat SF
Cancer Immunol Immunother; 2021 Feb; 70(2):265-273. PubMed ID: 32757054
[TBL] [Abstract][Full Text] [Related]
11. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
[TBL] [Abstract][Full Text] [Related]
12. Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma.
Grimm MO; Leucht K; Foller S
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830621
[TBL] [Abstract][Full Text] [Related]
13. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values.
Adashek JJ; Genovese G; Tannir NM; Msaouel P
Cancer Treat Res Commun; 2020 Jan; 23():100166. PubMed ID: 31935623
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
16. First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
Vano YA; Ladoire S; Elaidi R; Dermeche S; Eymard JC; Falkowski S; Gross-Goupil M; Malouf G; Narciso B; Sajous C; Tartas S; Voog E; Ravaud A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771710
[TBL] [Abstract][Full Text] [Related]
17. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740533
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for the treatment of renal cell carcinoma.
Di Bona C; Stühler V; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1157-1164. PubMed ID: 34042015
[TBL] [Abstract][Full Text] [Related]
20. Recent pharmacological approaches for the treatment of renal cell carcinoma.
Alimohammadi A; Fajkovic H; Remzi M; Shariat S; Schmidinger M
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):187-195. PubMed ID: 35285369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
